Drugs & Therapy Perspectives

, Volume 17, Issue 10, pp 13–15 | Cite as

Aftermath of myocardial infarction: ACE inhibitors prove their worth

Drug economics and quality of life
  • 10 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Le Pen C, Levy P. Le coût des maladies cardiovasularies. In: Grandjbakhch I, Ollivier JP, Pavie A, et al. La maladie coronaire: approches stratégiques et thérapeutiquies. Paris: Arnette Blackwell, 1995Google Scholar
  2. 2.
    Erhardt L, Ball S, Andersson F, et al. Cost effectiveness in the treatment of heart failure with ramipril. Pharmacoeconomics 1997; 12: 256–66PubMedCrossRefGoogle Scholar
  3. 3.
    Michel BC, Al MJ, Remme WJ, et al. Economic aspects of treatment with Captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands. Eur Heart J 1996; 7: 731–40CrossRefGoogle Scholar
  4. 4.
    Erhardt L, Caidahl K, Eriksson H, et al. Hjärstvikt [Heart failure]. Stockholm: socialstyrelsen [The National Board of Health and Welfare], 1994 (SoS-report 1994: 3)Google Scholar
  5. 5.
    McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. Pharmacoeconomics 1996; 9: 188–97PubMedCrossRefGoogle Scholar
  6. 6.
    Pfeffer MA, Braunwald E, Moye LA, et al. Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669–77PubMedCrossRefGoogle Scholar
  7. 7.
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8Google Scholar
  8. 8.
    Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–6PubMedCrossRefGoogle Scholar
  9. 9.
    Megarry SG, Sapsford R, Hall AS, et al. Do ACE inhibitors provide protection for the heart in the clinical setting of acute myocardial infarction? Drugs 1997; 54 Suppl. 5; 48–58PubMedCrossRefGoogle Scholar
  10. 10.
    Davie AP. ACE inhibitors after myocardial infarction: clinical and economic considerations. Pharmacoeconomics 2000 Mar; 7 (3): 237–43CrossRefGoogle Scholar
  11. 11.
    Le Pen C, Levy E, Bonte J. Cost-effectiveness analysis of Captopril treatment after myocardial infarction. Arch Mal Coeur Vaiss 1994; 87: 775–81PubMedGoogle Scholar
  12. 12.
    Szucs T, Berger K, Schulte-Hillen J, et al. Cost effectiveness of Captopril after myocardial infarction. Med Klinik 1996; 91: 112–8Google Scholar
  13. 13.
    Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of Captopril therapy after myocardial infarction. J Am Coll Cardiol 1995; 26: 914–9PubMedCrossRefGoogle Scholar
  14. 14.
    Hummel S, Piercy J, Wright R, et al. An economic analysis of the survival and ventricular enlargement (SAVE) study. Pharmacoeconomics 1997; 12: 182–92PubMedCrossRefGoogle Scholar
  15. 15.
    LePen C, Lilliu H, Keller T, et al. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction. Pharmacoeconomics 1998; 14: 49–58PubMedCrossRefGoogle Scholar
  16. 16.
    McMurray K, McGuire A, Davie AP, et al. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. Eur Heart J 1997; 18: 1411–5PubMedCrossRefGoogle Scholar
  17. 17.
    Cleland JGF. ACE inhibitors for myocardial infarction: how should they be used? Eur Heart J 1995; 16: 153–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Personalised recommendations